AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
May 29, 2026 11:30 AM EDT
News Briefing
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
AstraZeneca breast cancer pill faces review delay from regulators
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
ICON audit found revenue was overstated in 2023 and 2024; Psilera and Secretome Therapeutics raise funds.
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
